Table 2.

Results of a Cox proportional hazards model investigating association of time between advanced diagnosis and cohort entry time (months from advanced diagnosis to entry) with survival.

Factors	Estimate	95% CI
Months from advanced diagnosisa to entry	1.018	1.013–1.022
Male	1.200	1.139–1.264
Age at advanced diagnosis	1.012	1.009–1.014
Histology: squamous	1.201	1.120–1.287
Histology: unknown	1.392	1.240–1.563
Months from Jan-2011 to advanced diagnosisa	0.998	0.997–1.000

Note: In an unadjusted model, the coefficient of "Months from advanced diagnosis to entry" is 1.020 (1.016–1.025). The model is stratified by smoking, whether cancer is recurrent, and baseline EGFR status.

^aAdvanced NSCLC diagnosis refers to the diagnosis of stage IIIB or IV disease, or the diagnosis of a recurrence (progression) of initial early-stage disease; this differs from the initial diagnosis, which refers to the earliest diagnosis for NSCLC, regardless of stage at that moment.